Skip to content Skip to footer
Subscribe Now
Deal Maker of the Year 2021 (Part 01)
INSIGHTS+
Deal Maker of the Year 2021 (Part 01)
Shots: AstraZeneca and Roche were the top dealmakers completed 33 deals with multiple pharma and biotech companies and universities for a total deal value of $6.2B & $25.83B The highest value deal was AstraZeneca’s partnership with Ionis for the development and commercialization of Eplontersen signed on Dec. 7, 2021. Merck and Pfizer are among the…
January 7, 20220Comments
Insights+ Key Biosimilars Events of December 2021
INSIGHTS+
Insights+ Key Biosimilars Events of December 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Samsung Bioepis presented five-year follow-up results of…
January 6, 20220Comments
Viewpoints_Dr. Justin Odegaard_Dr. Yoshiaki Nakamura
VIEWPOINTS
PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insights on the Data of Guardant360 Liquid Biopsy Test Published in Nature Medicine
In an interview with PharmaShots, Justin Odegaard, Vice President of Clinical Development and a Laboratory Director at Guardant Health & Yoshiaki Nakamura, Staff Physician in the Department of Gastroenterology and Gastrointestinal Oncology shared their views on the benefits of using the Guardant360 liquid biopsy test in P-II (TRIUMPH) study for HER2-driven metastatic colorectal cancer Shots: The P-II (TRIUMPH) study evaluates pertuzumab +…
January 5, 20220Comments
PharmaShots Interview Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology
VIEWPOINTS
PharmaShots Interview: Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology
In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & Rheumatology Shots: The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
January 4, 20220Comments
PharmaShots Interview Alto Neuroscience’s Dr. Amit Etkin Shares Insights on the Future of Psychiatric Medicines
VIEWPOINTS
PharmaShots Interview: Alto Neuroscience’s Dr. Amit Etkin Shares Insights on the Future of Psychiatric Medicines
In an interview with PharmaShots, Dr. Amit Etkin, CEO and Founder of Alto Neuroscience shared his views on its clinical stage pipeline in the emerging hot precision psychiatry space. He also put his views on the funding received by the company for the development of its pipeline. Shots: Using precision psychiatry, the company’s human data R&D platform identifies brain biomarkers…
January 3, 20220Comments
Viewpoints_Joe Eazor
VIEWPOINTS
PharmaShots Interview: Clario’s Joe Eazor Shares Insight on the Clinical Trial Innovation and Evidence
In an interview with PharmaShots, Joe Eazor, CEO at Clario share his views on the ERT’s merger with Bioclinica to become Clario for clinical trial innovation and evidence ERT & Bioclinica merged to become Clario, following its Apr 2021 merger agreement & to generate the clinical evidence, empower the patients &  transform their lives by providing better evidence Clario combines Bioclinica's expertise in imaging,…
December 30, 20210Comments
Viewpoints_Shannon Burke
VIEWPOINTS
PharmaShots Interview: Synchrony’s Shannon Burke Shares Insight on Healthcare Consumerism
In an interview with PharmaShots, Shannon Burke, Synchrony Senior Vice President, and General Manager, Health Systems, share her views on healthcare financing & empowers the patients to pay for their healthcare Synchrony’s CareCredit card is a comprehensive healthcare financial solution that is designed for health and wellness needs. The CareCredit solution helps health systems, reduce accounts receivable, increase revenue,…
December 29, 20210Comments
Viewpoints_Andrew Hall
VIEWPOINTS
PharmaShots Interview: IMV’s Andrew Hall Shares Insight on DPX Technology for Bladder and Ovarian Cancer
In an interview with PharmaShots, Andrew Hall, CEO at IMV share his views on the data of  DPX delivery platform in the bladder and ovarian cancer, presented in two e-posters at the AACR-NCI-EORTC virtual conference Shots: The company has reported additional data to support the immunotherapeutic capabilities of its DPX technology. In pre-clinical/clinical data, DPX technology generates peptide-specific, T cell-based immune…
December 28, 20210Comments
Exclusive_Jeremiah Robison_2021
EXCLUSIVE
Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Share Insight on the New Data of Neural Sleeve for Neurological & other Disorders
In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the data of the Neural Sleeve gait study for patients with cerebral palsy, MS, stroke, and other neurological disorders Shots: Cionic has reported the results from the Neural Sleeve gait study which was conducted in the San Francisco Bay Area. The study showed an…
December 27, 20210Comments